SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Update Stake in SpringWorks Therapeutics to 1.7%

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in SpringWorks Therapeutics Inc. as of April 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, collectively beneficially own 1,258,386 shares of SpringWorks Therapeutics Inc. Common Stock.
• This aggregate amount represents 1.7% of the class of securities outstanding.
• FMR LLC holds sole voting power over 1,258,067 shares and sole dispositive power over 1,258,386 shares.
• Abigail P. Johnson holds sole dispositive power over 1,258,386 shares, with no sole or shared voting power.
• The filing is an Amendment No. 5 to a previous Schedule 13G, indicating an update to their reported ownership.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine beneficial ownership disclosure and does not contain performance or strategic updates for the issuer.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding SpringWorks Therapeutics Inc.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure by a major institutional investor, FMR LLC, and its principal, Abigail P. Johnson, regarding their passive ownership stake in SpringWorks Therapeutics Inc. Such filings are common in the investment industry and reflect portfolio adjustments or ongoing investment positions rather than specific strategic moves related to the issuer's industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which is below the 5% threshold for active influence.

Key Dates

Keywords

SpringWorks Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing